{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:20:55Z","timestamp":1777922455691,"version":"3.51.4"},"reference-count":38,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>Malignant mesotheliomas (MMs) are aggressive therapy-resistant tumors that generally have a poor prognosis. We previously reported the establishment of four new monoclonal antibodies (mAbs) for the diagnosis and treatment of MM. In this report, we characterized one of these antibodies, JMAM-1. The molecules whose antibodies were calibrated were picked up, transfected assuming CD10, and elucidated by fluorescence activated cell sorter. Survival experiments were performed using tumor-bearing mice model. JMAM-1 mAb was found to bind with CD10 antigen. The Kaplan\u2013Meier survival curve showed a small but prolonged survival effect. JMAM-1 mAb-treated MSTO-211H cells showed increased cell cycle arrest involved by cyclin-dependent-kinase. JMAM-1 antibody has cytostatic effect and may be a candidate for the treatment of MM. Among mesothelioma, CD10-positive cases have been reported to have a poorer prognosis than negative cases, which can be used as a tool for diagnosis.<\/jats:p>","DOI":"10.1089\/mab.2020.0033","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T10:43:57Z","timestamp":1614163437000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["A New CD10 Antibody Inhibits the Growth of Malignant Mesothelioma"],"prefix":"10.1177","volume":"40","author":[{"given":"Natsuko","family":"Mizutani","sequence":"first","affiliation":[{"name":"Department of Medical Technology, Faculty Health Sciences, Kyorin University, Tokyo, Japan."},{"name":"Department of Immunological Diagnosis, Graduate School of Medicine, Juntendo University, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oncology and School of Medicine, Juntendo University, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Kajino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oncology and School of Medicine, Juntendo University, Tokyo, Japan."},{"name":"Department of Human Pathology, School of Medicine, Juntendo University, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Immunological Diagnosis, Graduate School of Medicine, Juntendo University, Tokyo, Japan."},{"name":"Department of Pathology, Oncology and School of Medicine, Juntendo University, Tokyo, Japan."},{"name":"Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-016-2128-x"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","unstructured":"Oury TD Roggli VL and Sporn TA : Pathology of Asbestos-Associated Diseases. Springer Verlag Berlin Heidelberg 2014.","DOI":"10.1007\/978-3-642-41193-9"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31815608d9"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826915f1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(99)70469-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.146"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318211127a"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1808"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1073-8"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182519d96"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31826915f1"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65253-4"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","unstructured":"Shipp MA and Look AT: Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key! Blood 1993;82:1052\u20131070.","DOI":"10.1182\/blood.V82.4.1052.bloodjournal8241052"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.11.5.9141502"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-002-0639-4"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2010.03534.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0383"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-005-0141-6"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178376"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01987.x"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-7-3"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-011-1084-z"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.238"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02099.x"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1309\/TNKL7GDC66R9WPV5"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.5858\/2006-130-823-EORCCM"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.289"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1165"},{"key":"e_1_3_4_30_2","first-page":"5526","article-title":"CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: Implications for the design of novel peptide prodrugs for the therapy of CD10(+) tumors","volume":"63","author":"Pan C","year":"2003","unstructured":"Pan C, , Cardarelli PM, , Nieder MH, , Pickford LB, , Gangwar S, , King DJ, , Yarranton GT, , Buckman D, , Roscoe W, , Zhou F, , Salles A, , Chen TH, , Horgan K, , Wang YH, , Nguyen T, , and Bebbington CR: CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: Implications for the design of novel peptide prodrugs for the therapy of CD10(+) tumors. Cancer Res, 2003; 63:5526\u20135531.","journal-title":"Cancer Res"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00037310"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4374-x"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-9-30"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00731.x"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-016-0468-4"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2165"},{"key":"e_1_3_4_37_2","first-page":"2","article-title":"p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers","volume":"154","author":"Lioyd RV","year":"1999","unstructured":"Lioyd RV, , Erickson LA, , Jin L, , Kulig E, , Qian X, , Cheville JC, , and Scheithauer BW: p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol, 1999; 154:2.","journal-title":"Am J Pathol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14841"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.04.003"}],"container-title":["Monoclonal Antibodies in Immunodiagnosis &amp; Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mab.2020.0033","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2020.0033","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mab.2020.0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:21:11Z","timestamp":1777666871000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mab.2020.0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["10.1089\/mab.2020.0033"],"URL":"https:\/\/doi.org\/10.1089\/mab.2020.0033","relation":{},"ISSN":["2167-9436","2167-9436"],"issn-type":[{"value":"2167-9436","type":"print"},{"value":"2167-9436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}